BACE2, Asp1, CT, Blocking Peptide (Beta-site APP Cleaving Enzyme, Aspartyl Protease 2, DRAP, Down Re

Peptide corresponding to amino acids 496 to 511 of human BACE2 (4). Accumulation of the amyloid-b (Ab) plaque in the cerebral cortex is a critical event in the pathogenesis of Alzheimer's disease. Ab peptide is generated by proteolytic cleavage of the b-amyloid protein precursor (APP) at b-and g-sites by proteases. The long-sought b-secretase was recently identified by several groups independently and designated beta-site APP cleaving enzyme (BACE) and aspartyl protease 2 (Asp2) (1-4). A BACE homolog was recently cloned and designated BACE2, Asp1, DRAP (for Down region aspartic protease), and memapsin 1 (4-9). BACE2 also cleaves APP at b-site and at a different site within Ab (8). BACE2 locates on chromosome 21q22.3, the so-called 'Down critical region', suggesting that BACE2 and Ab may also contribute to the pathogenesis of Down syndrome (6,7) , Applications: , Suitable for use in ELISA, Western Blotting. Other applications not tested. Positive Control: Human heart tissue lysate can be used as positive control. , Storage and Stability:, May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50%). Freeze at -20°C or colder. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.